129 related articles for article (PubMed ID: 15168660)
21. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
[TBL] [Abstract][Full Text] [Related]
22. Postprandial lipoproteins and the molecular regulation of vascular homeostasis.
Botham KM; Wheeler-Jones CP
Prog Lipid Res; 2013 Oct; 52(4):446-64. PubMed ID: 23774609
[TBL] [Abstract][Full Text] [Related]
23. Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations.
Bradley WA; Gianturco SH
J Intern Med Suppl; 1994; 736():33-9. PubMed ID: 7986306
[TBL] [Abstract][Full Text] [Related]
24. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
25. Regulation of lipoprotein lipase secretion in murine macrophages during foam cell formation in vitro. Effect of triglyceride-rich lipoproteins.
Sofer O; Fainaru M; Schafer Z; Goldman R
Arterioscler Thromb; 1992 Dec; 12(12):1458-66. PubMed ID: 1450177
[TBL] [Abstract][Full Text] [Related]
26. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI.
Hu L; van der Hoogt CC; Espirito Santo SM; Out R; Kypreos KE; van Vlijmen BJ; Van Berkel TJ; Romijn JA; Havekes LM; van Dijk KW; Rensen PC
J Lipid Res; 2008 Jul; 49(7):1553-61. PubMed ID: 18367731
[TBL] [Abstract][Full Text] [Related]
27. Evidence of macrophage foam cell formation by very low-density lipoprotein receptor: interferon-gamma inhibition of very low-density lipoprotein receptor expression and foam cell formation in macrophages.
Kosaka S; Takahashi S; Masamura K; Kanehara H; Sakai J; Tohda G; Okada E; Oida K; Iwasaki T; Hattori H; Kodama T; Yamamoto T; Miyamori I
Circulation; 2001 Feb; 103(8):1142-7. PubMed ID: 11222479
[TBL] [Abstract][Full Text] [Related]
28. beta-VLDL and acetylated-LDL binding to pigeon monocyte macrophages.
Henson DA; St Clair RW; Lewis JC
Atherosclerosis; 1989 Jul; 78(1):47-60. PubMed ID: 2667527
[TBL] [Abstract][Full Text] [Related]
29. Macrophage foam cells from human aortic fatty streaks take up beta-VLDL and acetylated LDL in primary culture.
Jaakkola O; Ylä-Herttuala S; Särkioja T; Nikkari T
Atherosclerosis; 1989 Oct; 79(2-3):173-82. PubMed ID: 2688664
[TBL] [Abstract][Full Text] [Related]
30. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass.
Milosavljevic D; Kontush A; Griglio S; Le Naour G; Thillet J; Chapman MJ
Biochim Biophys Acta; 2003 Feb; 1631(1):51-60. PubMed ID: 12573449
[TBL] [Abstract][Full Text] [Related]
31. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism.
Kawakami A; Tani M; Chiba T; Yui K; Shinozaki S; Nakajima K; Tanaka A; Shimokado K; Yoshida M
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):424-9. PubMed ID: 15591219
[TBL] [Abstract][Full Text] [Related]
32. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis.
Patel KM; Strong A; Tohyama J; Jin X; Morales CR; Billheimer J; Millar J; Kruth H; Rader DJ
Circ Res; 2015 Feb; 116(5):789-96. PubMed ID: 25593281
[TBL] [Abstract][Full Text] [Related]
33. [Effects of oxidatively modified low density lipoprotein and very low density lipoprotein on the expression of MCP-1 in macrophages].
Wang G; Deng Z; Qu Z
Zhonghua Yi Xue Za Zhi; 1997 Mar; 77(3):212-5. PubMed ID: 9596963
[TBL] [Abstract][Full Text] [Related]
34. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
35. Hypertriglyceridemia: lipoprotein receptors and atherosclerosis.
Gianturco SH; Gotto AM; Bradley WA
Adv Exp Med Biol; 1985; 183():47-71. PubMed ID: 4036704
[TBL] [Abstract][Full Text] [Related]
36. UFM1 Protects Macrophages from oxLDL-Induced Foam Cell Formation Through a Liver X Receptor α Dependent Pathway.
Pang Q; Xiong J; Hu XL; He JP; Liu HF; Zhang GY; Li YY; Chen FL
J Atheroscler Thromb; 2015; 22(11):1124-40. PubMed ID: 26040753
[TBL] [Abstract][Full Text] [Related]
37. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice.
Draijer R; Volger OL; Dahlmans VE; de Wit EC; Havekes LM; Princen HM
Biochem Pharmacol; 2002 May; 63(9):1755-61. PubMed ID: 12007578
[TBL] [Abstract][Full Text] [Related]
38. Complete down-regulation of low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2 by beta-migrating very-low-density lipoprotein and non-lipoprotein cholesterol. Different cellular regulatory pools of cholesterol.
Kamps JA; van Berkel TJ
Eur J Biochem; 1992 Jun; 206(3):973-8. PubMed ID: 1318843
[TBL] [Abstract][Full Text] [Related]
39. Activation of peroxisome proliferator-activated receptor δ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein.
Bojic LA; Sawyez CG; Telford DE; Edwards JY; Hegele RA; Huff MW
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2919-28. PubMed ID: 23023367
[TBL] [Abstract][Full Text] [Related]
40. Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia.
Bersot TP; Innerarity TL; Mahley RW; Havel RJ
J Clin Invest; 1983 Sep; 72(3):1024-33. PubMed ID: 6309903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
